Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Feature
  • Published:

Public biotech 2007—the numbers

Nature Biotechnology volume 26, pages 753–762 (2008)Cite this article

A Corrigendum to this article was published on 01 October 2008

This article has been updated

Record profits and financing in the public biotech sector may be unsustainable in the coming years as economies falter.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Public biotech company revenue, R&D spending, profits and number of employees by market cap.
Figure 2: Global biotech industry financing.
Figure 3: Global biotech initial public offerings.
Figure 4: Public biotech companies by geographical location.

Change history

  • 09 October 2008

    In the version of this article initially published, in Table 6, two company names appeared in the incorrect columns. GlaxoSmithKline should be the Acquirer (not the Target) and Reliant should be the Target (not the Acquirer). The error has been corrected in the HTML and PDF versions of the article.

References

  1. Ernst & Young . Beyond Borders: Global Biotechnology Report 2008 (Ernst and Young, Global Biotechnology Center, Boston, May 2008).

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Data retrieval for this article was by Riku Lähteenmäki, a freelance writer in Turku, Finland.,

    Stacy Lawrence

  2. Stacy Lawrence, BioCentury senior writer, provided the analysis. Additional comments were provided by Nature Biotechnology editor-at-large John Hodgson.,

    Riku Lähteenmäki

Authors
  1. Stacy Lawrence
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Riku Lähteenmäki
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lawrence, S., Lähteenmäki, R. Public biotech 2007—the numbers. Nat Biotechnol 26, 753–762 (2008). https://doi.org/10.1038/nbt0708-753

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nbt0708-753

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing